SCHEDULE: Sol-Gel Technologies Shareholder Update

Moshe Arkin and Arkin Dermatology Ltd. report increased beneficial ownership in Sol-Gel Technologies following a recent offering.

Summary

• This filing is an amendment to a Schedule 13D, reporting changes in beneficial ownership of Sol-Gel Technologies Ltd. ordinary shares.
• The amendment is primarily to update percentage holdings after the closing of an underwritten offering on March 25, 2026.
• As of March 25, 2026, Arkin Dermatology Ltd. beneficially owns 1,806,856 ordinary shares, representing approximately 52.44% of the company's outstanding shares.
• Moshe Arkin directly owns 143,257 ordinary shares, representing approximately 4.41% of the company's outstanding shares.
• Moshe Arkin, as the sole shareholder and director of Arkin Dermatology Ltd., may also be deemed the indirect beneficial owner of the shares held by Arkin Dermatology Ltd.
• The total beneficial ownership for Moshe Arkin, including direct and indirect holdings, is 1,950,113 ordinary shares, representing approximately 56.60% of the company's outstanding shares.
• The percentages are based on 3,245,270 ordinary shares outstanding on March 25, 2026, as per a prospectus filed on March 24, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on existing ownership stakes and a completed capital raise, without providing new operational or financial performance data.

Positives

• Moshe Arkin and Arkin Dermatology Ltd. have increased their aggregate beneficial ownership to 56.60% of Sol-Gel Technologies' outstanding shares.
• The reporting persons hold significant voting and dispositive power over the shares they beneficially own.

Future Outlook

No specific future outlook or guidance is provided in this filing, which solely concerns beneficial ownership updates.

Industry Context

StockSavvy.ai notes that this Schedule 13D filing indicates a significant concentration of ownership by Moshe Arkin and Arkin Dermatology Ltd. in Sol-Gel Technologies, following a recent equity offering. Such filings are crucial for understanding control and potential strategic shifts within a company, especially in the biotechnology sector where significant investments are common.

Stakeholder Impact

• Shareholders: The increased concentration of ownership by Moshe Arkin and Arkin Dermatology Ltd. may influence future strategic decisions and potentially impact share price dynamics.
• Management and Board: Significant ownership concentration can lead to greater alignment or potential conflicts between controlling shareholders and other stakeholders.

Key Dates

Keywords

Sol-Gel Technologies, Schedule 13D, Beneficial Ownership, Moshe Arkin, Arkin Dermatology Ltd., Shareholder, Securities Filing, SEC, Ordinary Shares, Underwritten Offering